<DOC>
	<DOCNO>NCT02045693</DOCNO>
	<brief_summary>The purpose study assess effect steady state DCV/ASV/BMS-791325 fix dose combination ( FDC ) + 75mg BMS-791325 Pharmacokinetics ( PK ) Methadone subject stable dose Methadone PK Buprenorphine subject stable dose Buprenorphine .</brief_summary>
	<brief_title>Drug Interaction &amp; Methadone &amp; Buprenorphine</brief_title>
	<detailed_description>IND number : 101,943 Primary purpose : Other : Phase 1 Clinical Pharmacology drug interaction study healthy subject</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subject must stable Methadone Buprenorphine regimens least 28 day prior screen Subjects must healthy except history Methadone Buprenorphine treatment regimens Prior exposure DCV , ASV BMS791325 within 3 month screen investigational drug placebo within 4 week study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>